Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating guadecitabine in combination with donor lymphocyte infusion for acute myeloid leukemia, chronic myelomonoc…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia [Phase 2]
Phase 2 trial evaluating geriatric assessment and genetic profiling to personalize therapy for older adults with acute myeloid leukemia; the…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation [Phase 1]
Phase 1 trial evaluating maintenance therapy with the IDH1 inhibitor ivosidenib after allogeneic stem cell transplantation in IDH1-mutant my…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study of the combination omacetaxine mepesuccinate and venetoclax in relapsed or refractory a…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment [NA]
A completed clinical trial evaluating the LEAP AI-assisted evaluation platform versus clinician-only assessment in acute promyelocytic leuke…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating reduced-intensity conditioning before allogeneic donor stem cell transplantation in patients with high-risk hematol…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant [Phase 2]
This clinical trial update reports that the Phase 2 study of MT-401 in patients with acute myeloid leukemia following stem cell transplantat…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia [Phase 1]
A Phase 1 study evaluating a combination of Gemtuzumab ozogamicin and Midostaurin with standard cytarabine and daunorubicin in newly diagnos…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance [Phase 2]
This Phase 2 trial update describes a precision genomic strategy to assess mutation clearance in acute myeloid leukemia. The study is curren…
-
CLINICAL_TRIALS trial_result · 2025-10-27Clinical Trial Update: Resiliency in Older Adults Undergoing Bone Marrow Transplant
A completed clinical trial update from Johns Hopkins on resiliency in older adults undergoing bone marrow transplant for hematologic cancers…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating a CD8-depleted, non-engrafting, HLA-mismatched unrelated donor infusion in patients with myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2025-10-22Clinical Trial Update: Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML [Phase 1]
Phase 1 clinical trial update evaluating eganelisib as a monotherapy and in combination with cytarabine in relapsed/refractory acute myeloid…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) [Phase 1]
Phase 1 clinical trial evaluating the administration of donor-derived multi TAA-specific T cells (ADSPAM) for acute myeloid leukemia or myel…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 study evaluating uproleselan with cladribine and low-dose cytarabine in patients with treated secondary acute myeloid leukemia; re…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia [Phase 1]
Phase 1 trial update for entrectinib in combination with ASTX727 in relapsed/refractory TP53-mutated acute myeloid leukemia; the study is cu…
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Epigenetic Reprogramming in Relapse/Refractory AML [Phase 1]
Phase 1 clinical trial update reports results of an epigenetic reprogramming therapy for relapse/refractory acute myeloid leukemia, with res…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: CD123 Redirected T Cells for AML in Pediatric Subjects [Phase 1]
Phase 1 trial of CD123-targeted T cells for acute myeloid leukemia in pediatric patients and those with relapse or refractory disease has be…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation [Phase 1]
A Phase 1 trial evaluates enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms after allogeneic stem cell transplantation. Th…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. [Phase 1]
Phase 1 study evaluating siremadlin with venetoclax and azacitidine in adults with acute myeloid leukemia ineligible for chemotherapy has be…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) [Phase 1]
This update reports termination of the first-in-human Phase 1 trial of the VOB560-MIK665 combination in relapsed/refractory hematologic mali…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in patients with hematologic and myeloproliferative malignancies. …
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) [Phase 3]
A Phase 3 trial comparing venetoclax plus azacitidine to standard of care after allogeneic stem cell transplantation in acute myeloid leukem…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
This completed multicenter retrospective study collected data on patients with acute myeloid leukemia with core binding factor rearrangement…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 [Phase 3]
A Phase 3 trial evaluates Galinpepimut-S as maintenance therapy versus investigator's choice of best available therapy in acute myeloid leuk…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study of JNJ-74856665 in participants with Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia has…